title: The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.
abstract: The aim of the study was to examine lipid profiles, arterial stiffness (AS), carotid intima-media thickness (cIMT), in 55 women with RA without overt cardiovascular disease (СVD) treated with rituximab (RTX).The following parameters were recorded before and 24 weeks after RTX therapy (2 infusions of 500 or 1,000 mg RTX intravenously, fortnightly): plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, DAS 28-ESR, serum C-reactive protein (CRP), RF IgM, AS (SI - stiffness index, RI - reflection index) by digital volume pulse contour analysis (Micro Medical, UK), and common cIMT by high-resolution B-mode carotid ultrasound. Based on the European League Against Rheumatism (EULAR) criteria, patients were divided into two groups: 1) moderate/good response to RTX therapy after 24 weeks (41 patients, 75%), 2) no response to RTX therapy (14 patients, 25%). Effective RTX therapy resulted in 9% increase in TC, 23% increase in HDL-C and 14% decrease in atherogenic index, 57% decrease in SI and 24% decrease in RI. We observed a 9% decrease of cIMTmax at 24 weeks. The improvement of cardiovascular parameters was accompanied by statistically significant decreases of CRP, ESR, RF IgM and DAS 28 in group 1 (P < 0.05). There were not significant changes in lipid profile, AS parameters, and cIMT in group 2. Two infusions of RTX in case of moderate/good EULAR effect of therapy exerted favorable effects on lipid profile, AS and cIMT in women with RA without overt CVD.
authors.affiliation: Department of Instrumental and Ultrasound Diagnostics, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Diana S
authors.identifier: 0000-0003-0840-1549
authors.initials: DS
authors.lastname: Novikova
authors.affiliation: Department of Systemic Rheumatic Diseases, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Tatiana V
authors.identifier: 0000-0001-5793-4689
authors.initials: TV
authors.lastname: Popkova
authors.affiliation: Department of Early Arthritis, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Galina V
authors.identifier: 0000-0001-7958-5926
authors.initials: GV
authors.lastname: Lukina
authors.affiliation: Department of Early Arthritis, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Elena L
authors.identifier: 0000-0002-6519-1106
authors.initials: EL
authors.lastname: Luchikhina
authors.affiliation: Department of Early Arthritis, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Dmitry E
authors.identifier: 0000-0002-2352-4080
authors.initials: DE
authors.lastname: Karateev
authors.affiliation: Department of Instrumental and Ultrasound Diagnostics, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Alexander V
authors.identifier: 0000-0003-1784-3699
authors.initials: AV
authors.lastname: Volkov
authors.affiliation: Department Immunology and Molecular Biology, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Alexander A
authors.identifier: 0000-0002-2738-2956
authors.initials: AA
authors.lastname: Novikov
authors.affiliation: Department Immunology and Molecular Biology, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Elena N
authors.identifier: 0000-0003-4074-5907
authors.initials: EN
authors.lastname: Aleksandrova
authors.affiliation: V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
authors.forename: Evgeny L
authors.identifier: 0000-0002-7177-2409
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000150:complications; D059168:Carotid Intima-Media Thickness; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D059289:Vascular Stiffness
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D000069283:Rituximab; D002097:C-Reactive Protein
keywords: Arterial Stiffness; Carotid Atherosclerosis; Lipids; Rheumatoid Arthritis; Rituximab
references.citation: Expert Opin Drug Saf. 2015 Jun;14(6):839-44
references.pmid: 25802019
references.citation: Nat Rev Rheumatol. 2015 Feb;11(2):69-70
references.pmid: 25536484
references.citation: Rheumatology (Oxford). 2003 Feb;42(2):244-57
references.pmid: 12595618
references.citation: Ann Rheum Dis. 2013 Apr;72(4):560-5
references.pmid: 22589377
references.citation: Cerebrovasc Dis. 2004;18(4):346-9
references.pmid: 15523176
references.citation: Rheumatol Int. 2015 Jun;35(6):1059-67
references.pmid: 25540049
references.citation: Curr Pharm Des. 2012;18(11):1512-8
references.pmid: 22364135
references.citation: J Am Heart Assoc. 2014 Oct;3(5):e001267
references.pmid: 25336464
references.citation: Ann Rheum Dis. 2013 Sep 1;72(9):1496-502
references.pmid: 23136242
references.citation: Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):296-302
references.pmid: 25359862
references.citation: Curr Pharm Des. 2012;18(11):1543-55
references.pmid: 22364138
references.citation: Clin Rheumatol. 2009 Jun;28(6):705-10
references.pmid: 19319624
references.citation: Curr Pharm Des. 2014;20(4):496-9
references.pmid: 23565629
references.citation: Scand J Rheumatol. 2013;42(3):190-5
references.pmid: 23286833
references.citation: Ann Rheum Dis. 2010 Sep;69(9):1649-54
references.pmid: 19628821
references.citation: Eur Heart J. 2003 Jun;24(11):987-1003
references.pmid: 12788299
references.citation: Rheumatology (Oxford). 2015 May;54(5):808-15
references.pmid: 25305139
references.citation: Clin Exp Rheumatol. 2011 Nov-Dec;29(6):942-50
references.pmid: 22153361
references.citation: Ann Med. 2015;47(6):457-67
references.pmid: 26340234
references.citation: Rheumatology (Oxford). 2012 Jun;51(6):1107-11
references.pmid: 22328565
references.citation: J Rheumatol. 2008 Mar;35(3):398-406
references.pmid: 18203326
references.citation: Curr Vasc Pharmacol. 2010 Jul;8(4):437-49
references.pmid: 19758114
references.citation: Arthritis Rheum. 2008 Dec 15;59(12):1821-4
references.pmid: 19035415
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: PLoS One. 2015;10(6):e0130709
references.pmid: 26114946
references.citation: Arthritis Rheum. 2008 Dec 15;59(12):1690-7
references.pmid: 19035419
references.citation: Curr Pharm Des. 2012;18(11):1450-6
references.pmid: 22364129
references.citation: Expert Opin Pharmacother. 2008 May;9(7):1121-8
references.pmid: 18422470
references.citation: Heart. 2012 Feb;98(3):177-84
references.pmid: 22095617
references.citation: Biologics. 2013;7:69-75
references.pmid: 23526116
references.citation: Ann Rheum Dis. 2015 Jun;74(6):1118-23
references.pmid: 24845391
references.citation: Eur Heart J. 2015 Feb 21;36(8):482-9c
references.pmid: 25433021
references.citation: Arthritis Rheum. 1996 Jan;39(1):34-40
references.pmid: 8546736
references.citation: J Hypertens. 2012 Mar;30(3):445-8
references.pmid: 22278144
references.citation: Arthritis Rheumatol. 2015 Jun;67(6):1449-55
references.pmid: 25776112